Compare Icl Group Ltd (ICL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Icl Group Ltd trades at $5.03 (market cap $6.47B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Icl Group Ltd pays a 4.11% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| ICL | XBI | |
|---|---|---|
Market Cap | $6.47B | $10.11B |
Volume | 1,387,140 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $6.84 | $169.55 |
52-Week Low | $4.80 | $104.99 |
Typical Hold Time | 56 Days | 38 Days |
Enterprise Value | $9.11B | — |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL Group trades at $5.015, down 1.28% today, with a bearish technical outlook despite recent earnings beats. The company maintains stable cash flow generation with $1.06B from operations in 2025, though revenue has declined from $10.0B in 2022 to $7.15B in 2025. Recent Q2 2026 results showed earnings of $0.12 per share, beating estimates, and the company announced a dividend of $0.06 payable September 16, 2026.
While ICL shows fundamental stability with reasonable valuation metrics (P/E 20.83, P/S 0.84), the stock faces headwinds from declining profitability margins and bearish technical signals. Analyst consensus remains neutral with 100% hold ratings, though the $6.08 price target suggests 21% upside potential from current levels.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
